Drug Profile
LY 133314
Latest Information Update: 21 Apr 1998
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Pyrrolidines
- Mechanism of Action Estrogen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 21 Apr 1998 Profile reviewed
- 21 Apr 1998 No-Development-Reported for Breast cancer in Italy (Unknown route)
- 25 Nov 1994 Preclinical development for Breast cancer in Italy (Unknown route)